These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 26306506)

  • 41. A Comparative
    Lankinen P; Noponen T; Autio A; Luoto P; Frantzèn J; Löyttyniemi E; Hakanen AJ; Aro HT; Roivainen A
    Contrast Media Mol Imaging; 2018; 2018():9892604. PubMed ID: 29681785
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [
    Sollini M; Trenti N; Malagoli E; Catalano M; Di Mento L; Kirienko A; Berlusconi M; Chiti A; Antunovic L
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1605-1615. PubMed ID: 31044264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early assessment with
    Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
    BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level.
    Bertagna F; Bosio G; Biasiotto G; Rodella C; Puta E; Gabanelli S; Lucchini S; Merli G; Savelli G; Giubbini R; Rosenbaum J; Alavi A
    Clin Nucl Med; 2009 Nov; 34(11):756-61. PubMed ID: 19851169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modest utility of quantitative measures in (18)F-fluorodeoxyglucose positron emission tomography scanning for the diagnosis of aortic prosthetic graft infection.
    Saleem BR; Berger P; Vaartjes I; de Keizer B; Vonken EJ; Slart RH; de Borst GJ; Zeebregts CJ
    J Vasc Surg; 2015 Apr; 61(4):965-71. PubMed ID: 25498161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis.
    Tian G; Xiao Y; Chen B; Xia J; Guan H; Deng Q
    Acta Radiol; 2010 Nov; 51(9):1002-6. PubMed ID: 20942732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In the evaluation of patients with skull base osteomyelitis, does 18F-FDG PET CT have a role?
    Kulkarni SC; Padma S; Shanmuga Sundaram P
    Nucl Med Commun; 2020 Jun; 41(6):550-559. PubMed ID: 32282638
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
    Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
    Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variations in (18)F-FDG uptake in breast cancer depending on PET/CT acquisition position.
    Lee JH; Jeon TJ; Ahn SG; Jeong J; Seok JW; Ryu YH
    Clin Radiol; 2016 Jan; 71(1):86-91. PubMed ID: 26646369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].
    Zhang TM; Zhang LM; Liu Y; Zhang ZF; Wang CL
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2901-4. PubMed ID: 23328236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study.
    Martin C; Castaigne C; Tondeur M; Flamen P; De Wit S
    HIV Med; 2013 Sep; 14(8):455-62. PubMed ID: 23517190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The diagnostic value of
    Kouijzer IJE; Scheper H; de Rooy JWJ; Bloem JL; Janssen MJR; van den Hoven L; Hosman AJF; Visser LG; Oyen WJG; Bleeker-Rovers CP; de Geus-Oei LF
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):798-805. PubMed ID: 29256136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
    Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
    Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.